STERIS (STE) Q2 2027 Earnings Call Transcript
STERIS (STE) reported Q2 2027 earnings with adjusted EBIT margin at 24.6%, up 150 bps YoY. Adjusted EPS grew 19% to $2.94. Revenue grew 7-8%, with Healthcare up 7%, AST up 5%, and Life Sciences up 18%. The company announced plans to acquire Xodus Medical. Full-year EPS outlook raised to $11.35-$11.55. Free cash flow was $492.5M for H1 2027.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise are likely to drive short‑term price appreciation, while debt levels warrant caution.
Market read
Steris' earnings beat and upgraded FY guidance provide a clear trading catalyst for the stock.
What to watch
Higher debt ratio (1.1x) and reduced free cash flow could constrain future buybacks.
Background
Steris reported Q2 2027 results, highlighting margin improvement, tariff refunds, and an acquisition announcement.
Ticker impact
Q2 2027 earnings call disclosed adjusted EPS of $2.94 and raised FY EPS guidance to $11.35‑$11.55, up from $11.10‑$11.30.
likely upward pressure as investors price in higher earnings outlook
Higher EPS guidance and solid margin expansion indicate better profitability; buyback capacity remains, supporting demand.
Market effects
Positive for medical device and healthcare equipment sector as Steris raises outlook.
U.S. healthcare equipment stocks may see modest gains.
Limited to investors tracking US healthcare equipment exposure.
Counterpoint
Guidance raise may already be priced in; focus on debt level and cash flow decline.
Key entities
- CompanySteris plc
Medical device manufacturer reporting Q2 2027 earnings.
- CompanyXodus Medical
Target of Steris acquisition announced during the call.
